TICKERNERD
Menu
NEUPNEUPHealthcare · Biotechnology

NEUP Stock Forecast: Neuphoria Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$3.93
+1.29% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$21.0M
Ticker Nerd rank
7 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
+2.1%
1M
+16.3%
YTD
+1.3%
1Y
−51.2%
From 52W high
−80.3%
From 52W low
+19.1%
$3
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NEUP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neuphoria Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
7 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Revisions
55
Volatility
52
Momentum
22
Issuance
15
Growth
8
Accruals
8
Value
5
Quality
3

Size (88): Smaller than most of the companies we track.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own Neuphoria Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

NEUP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NEUP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26NEUP

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
15 May 2026HC Wainwright & Co.DowngradeNeutral—
5 Dec 2025HC Wainwright & Co.MaintainsBuy—
11 Sept 2025Maxim GroupMaintainsBuy—
26 Aug 2025HC Wainwright & Co.ReiteratesBuy—
4 Feb 2025HC Wainwright & Co.MaintainsBuy—
1 Aug 2024HC Wainwright & Co.ReiteratesBuy$8.00
18 July 2024HC Wainwright & Co.ReiteratesBuy$8.00
12 June 2024HC Wainwright & Co.ReiteratesBuy$8.00
21 Mar 2024HC Wainwright & Co.ReiteratesBuy$8.00
7 Dec 2023HC Wainwright & Co.ReiteratesBuy$8.00
28 Sept 2023HC Wainwright & Co.UpgradeBuy$8.00
28 Sept 2023Maxim GroupMaintainsBuy$7.00 → $10
16 June 2023Maxim GroupInitiatesBuy$7.00
10 Mar 2023Evercore ISI GroupUpgradeOutperform$6.00
9 Mar 2023HC Wainwright & Co.MaintainsNeutral—
9 Mar 2023Loop CapitalMaintainsBuy$10 → $17
20 Dec 2022Evercore ISI GroupDowngradeIn-Line$17 → $6.00
19 Dec 2022HC Wainwright & Co.DowngradeNeutral—
1 Nov 2022Loop CapitalInitiatesBuy$23
10 Jan 2022BerenbergInitiatesBuy$21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

NEUP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Neuphoria Therapeutics, Inc. (NEUP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.1×

Cheaper than 70% of US stocks

Price / sales
−1580.6×

Cheaper than 99% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
110513.3%

Higher than 99% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−62.9%

Higher than 18% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NEUP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NEUPNeuphoria Therapeutics, Inc.$21.0M
7
ATOSAtossa Therapeutics, Inc.$20.6M
24
CLRBCellectar Biosciences, Inc.$20.5M
40
CVMCEL-SCI Corp.$20.3M
38
SKYESkye Bioscience, Inc.$20.0M
27
LGVNLongeveron, Inc.$21.9M
52
TVRDTvardi Therapeutics, Inc.$19.7M
22
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEUP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest NEUP news & analysis

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 24 July 2026negative

Investor rights law firm Halper Sadeh LLC is investigating the merger between Neuphoria Therapeutics Inc. and Scancell Holdings plc, under which Neuphoria shareholders would own 14.5% of the combined company, to determine whether Neuphoria is obtaining a fair price for its shareholders.

Why it matters — The investigation raises potential concerns about the fairness of the merger terms for Neuphoria shareholders, who would hold a minority stake in the combined entity.

FAQ

Frequently asked questions about NEUP stock

Is NEUP stock a buy right now?

Of the 1 analysts covering Neuphoria Therapeutics, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neuphoria Therapeutics, Inc. 7 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NEUP?

As at 1 Aug 2026, Neuphoria Therapeutics, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

What is the NEUP stock forecast for 2030?

No analyst covering Neuphoria Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEUP are extrapolating price history, which says nothing about the business.

How has NEUP stock performed over the past year?

Neuphoria Therapeutics, Inc. returned -51.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neuphoria Therapeutics, Inc. do?

Neuphoria Therapeutics Inc. is a biotech company engaged in the research and development of novel therapeutics, primarily focused on addressing unmet medical needs in mental health.

What is the latest news on NEUP?

The most recent item we track (Business Wire, 24 July 2026): "NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders". Investor rights law firm Halper Sadeh LLC is investigating the merger between Neuphoria Therapeutics Inc. and Scancell Holdings plc, under which Neuphoria shareholders would own 14.5% of the combined company, to determine whether Neuphoria is obtaining a fair price for its shareholders.

Company

About Neuphoria Therapeutics, Inc.

Neuphoria Therapeutics Inc. is a biotech company engaged in the research and development of novel therapeutics, primarily focused on addressing unmet medical needs in mental health. The company's work is pivotal within the biotech sector, as it explores innovative solutions for conditions such as depression and anxiety disorders, which affect millions worldwide. By leveraging cutting-edge technologies and collaborative research, Neuphoria Therapeutics aims to create effective treatments that can transform the landscape of mental health care. The influence of Neuphoria in the biotech industry is significant, as it contributes to the growing demand for specialized and advanced treatment options in the healthcare sector. Functioning in a space where breakthroughs can significantly enhance quality of life, Neuphoria Therapeutics is positioned as a key player in the push toward mental health advancements. As it progresses in its developmental pipeline, the company's activities remain closely watched by stakeholders in pharmaceuticals, healthcare providers, and patient communities.

CEO Dr. Spyridon Papapetropoulos M.D., Ph.D. · 7 employees · United States · https://www.neuphoriatx.com